Novartis teams with India’s Biological E for typhoid vaccine development

Novartis and Indian biopharma Biological E have entered into a development and licensing agreement  to deliver accessible and affordable typhoid and paratyphoid A vaccines to the developing world. Yearly, over 21 million cases and 5 million cases of typhoid and paratyphoid A fever respectively are reported, with many typhoid victims being children younger than two for which there is no …